Results 151 to 160 of about 11,898 (160)

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis

Journal of the Neurological Sciences, 2016
Carlo Pozzilli, Luca Prosperini
exaly  

Natalizumab

Reactions Weekly, 2017
openaire   +1 more source

Natalizumab

Reactions Weekly, 2018
  +4 more sources

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Multiple Sclerosis Journal, 2018
Mike P Wattjes, Birgit I Lissenberg-Witte, Theo Rispens   +2 more
exaly  

Erythroblastaemia in natalizumab-treated patients with multiple sclerosis

Multiple Sclerosis and Related Disorders, 2016
Sabrina Buoro, Matteo Vidali, Tommaso Mecca   +2 more
exaly  

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Acta Neurologica Scandinavica, 2014
Andrea Harrer, , Peter Wipfler
exaly  

Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation

Multiple Sclerosis and Related Disorders, 2017
Jai Perumal, Ulrike Kaunzner, Timothy Vartanian   +2 more
exaly  

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

Journal of Clinical Pharmacology, 2017
exaly  

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis

Journal of Clinical Pharmacology, 2016
exaly  

The relationship between inflammatory activity and brain atrophy in natalizumab treated patients

European Journal of Radiology, 2012
exaly